Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Rudolph Navari

AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018. PMID: 34613472.
      View in: PubMed
    2. Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035. PMID: 33878896.
      View in: PubMed
    3. Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459. PMID: 33442782.
      View in: PubMed
    4. Chow R, Chiu L, Herrstedt J, Aapro M, Lock M, DeAngelis C, Navari RM. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer. 2021 Aug; 29(8):4269-4275. PMID: 33409724.
      View in: PubMed
    5. Navari RM, Ruddy KJ, LeBlanc TW, Nipp R, Clark-Snow R, Schwartzberg L, Binder G, Bailey WL, Potluri R, Schmerold LM, Papademetriou E, Roeland EJ. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331. PMID: 33289268.
      View in: PubMed
    6. Aapro M, Navari RM, Roeland E, Zhang L, Schwartzberg L. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan; 157:103143. PMID: 33260048.
      View in: PubMed
    7. Loprinzi CL, Le-Rademacher JG, Navari RM. The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting-Reply. JAMA Oncol. 2020 11 01; 6(11):1812-1813. PMID: 32940634.
      View in: PubMed
    8. Navari RM, Roeland EJ. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24):1863-1872. PMID: 32543309.
      View in: PubMed
    9. Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp RD, Binder G, Sebastiani S, Potluri R, Schmerold L, Papademetriou E, Schwartzberg L, Navari RM. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2020 06; 18(6):676-681. PMID: 32502985.
      View in: PubMed
    10. Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 06 01; 6(6):895-899. PMID: 32379269.
      View in: PubMed
    11. Navari RM, Loprinzi CL. Olanzapine is an effective antiemetic agent. Ann Palliat Med. 2020 05; 9(3):628-630. PMID: 32498523.
      View in: PubMed
    12. Navari RM. Nausea and Vomiting in Advanced Cancer. Curr Treat Options Oncol. 2020 02 05; 21(2):14. PMID: 32025954.
      View in: PubMed
    13. Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597. PMID: 32162813.
      View in: PubMed
    14. Navari RM, Ruddy KJ, LeBlanc TW, Clark-Snow R, Wickham RJ, Binder G, Coberly T, Potluri R, Schmerold LM, Roeland EJ. Impact of Addition of Carboplatin AUC = 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. JCO Oncol Pract. 2020 02; 16(2):e132-e138. PMID: 31800352.
      View in: PubMed
    15. Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2019 Dec 04. PMID: 31801902.
      View in: PubMed
    16. Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210. PMID: 31709853.
      View in: PubMed
    17. Navari RM. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132. PMID: 31622113.
      View in: PubMed
    18. Chow R, Aapro M, Navari RM, Gralla R, Chiu N, Chiu L, Chan S, Popovic M, Lam H, Lock M, DeAngelis C. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186. PMID: 31419719.
      View in: PubMed
    19. Navari RM, Mosier MC. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. Onco Targets Ther. 2019; 12:3277-3284. PMID: 31118678.
      View in: PubMed
    20. Williams GR, Kenzik KM, Parman M, Al-Obaidi M, Francisco L, Rocque GB, McDonald A, Paluri R, Navari RM, Nandagopal L, Gbolahan O, Young-Smith C, Robertson M, Bhatia S. Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE). J Geriatr Oncol. 2020 03; 11(2):270-273. PMID: 31005648.
      View in: PubMed
    21. Kim H, Morgan DE, Schexnailder P, Navari RM, Williams GR, Bart Rose J, Li Y, Paluri R. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019 01; 54(1):16-22. PMID: 30138218.
      View in: PubMed
    22. Navari RM. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255. PMID: 30304952.
      View in: PubMed
    23. Navari RM, Schwartzberg LS. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. 2018; 11:6459-6478. PMID: 30323622.
      View in: PubMed
    24. Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540. PMID: 29722791.
      View in: PubMed
    25. Navari RM, Rapoport BL, Powers D, Arora S, Clark-Snow R. Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. Cancer Med. 2018 May 23. PMID: 29790666.
      View in: PubMed
    26. Chow R, Warr DG, Navari RM, Tsao M, Popovic M, Chiu L, Milakovic M, Lam H, DeAngelis C. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549. PMID: 29796708.
      View in: PubMed
    27. Schwartzberg LS, Navari RM. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun; 35(6):754-767. PMID: 29796927.
      View in: PubMed
    28. Navari RM. Managing Nausea and Vomiting in Patients With Cancer: What Works. Oncology (Williston Park). 2018 03 15; 32(3):121-5, 131, 136. PMID: 29548068.
      View in: PubMed
    29. Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, Schwartzberg L. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629. PMID: 28919712.
      View in: PubMed
    30. Ruddy KJ, Navari RM, Loprinzi CL. Thalidomide: Rebirth of a Gestational Antiemetic? J Clin Oncol. 2017 11 01; 35(31):3523-3524. PMID: 28872926.
      View in: PubMed
    31. Navari RM. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222. PMID: 28447301.
      View in: PubMed
    32. Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017 01; 25(1):303-308. PMID: 27815710.
      View in: PubMed
    33. Navari RM, Loprinzi ChL. Olanzapine for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 10 06; 375(14):1396. PMID: 27705262.
      View in: PubMed
    34. Chasen M, Urban L, Schnadig I, Rapoport B, Powers D, Arora S, Navari R, Schwartzberg L, Gridelli C. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer. 2017 01; 25(1):85-92. PMID: 27557833.
      View in: PubMed
    35. Navari R. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs Today (Barc). 2016 Aug; 52(8):431-438. PMID: 27722211.
      View in: PubMed
    36. Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 01; 25(1):277-288. PMID: 27443154.
      View in: PubMed
    37. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):134-42. PMID: 27410922.
      View in: PubMed
    38. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67. PMID: 27050207.
      View in: PubMed
    39. Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016 Apr; 14(4):141-7. PMID: 27152512.
      View in: PubMed
    40. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30. PMID: 26851398.
      View in: PubMed
    41. Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016 May; 24(5):2381-2392. PMID: 26768437.
      View in: PubMed
    42. Navari RM. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016; 15(3):343-56. PMID: 26699406.
      View in: PubMed
    43. Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E, DeAngelis C. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016 Feb; 24(2):1001-1008. PMID: 26530228.
      View in: PubMed
    44. Navari RM. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015; 15(10):1127-33. PMID: 26366937.
      View in: PubMed
    45. Navari RM. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:595894. PMID: 26421294.
      View in: PubMed
    46. Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep; 16(9):1079-1089. PMID: 26272769.
      View in: PubMed
    47. Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015 Sep; 16(9):1071-1078. PMID: 26272768.
      View in: PubMed
    48. Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46. PMID: 25838122.
      View in: PubMed
    49. Navari RM. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015; 9:155-61. PMID: 25552904.
      View in: PubMed
    50. Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608. PMID: 25323946.
      View in: PubMed
    51. Morrow GR, Navari RM, Rugo HS. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12(3 Suppl 9):1-14; quiz 15. PMID: 24874107.
      View in: PubMed
    52. Navari RM. Clinical trial data in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12 Suppl 9(3):5-8. PMID: 25855942.
      View in: PubMed
    53. Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014 Jan 05; 722:180-6. PMID: 24157985.
      View in: PubMed
    54. Navari R. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4. PMID: 23647207.
      View in: PubMed
    55. Alves NJ, Champion MM, Stefanick JF, Handlogten MW, Moustakas DT, Shi Y, Shaw BF, Navari RM, Kiziltepe T, Bilgicer B. Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site. Biomaterials. 2013 Jul; 34(22):5700-10. PMID: 23601661.
      View in: PubMed
    56. Navari RM. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62. PMID: 23404093.
      View in: PubMed
    57. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63. PMID: 23314603.
      View in: PubMed
    58. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA, Navari RM, Bilgicer B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012 Apr; 2(4):e64. PMID: 22829966.
      View in: PubMed
    59. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct; 9(5):188-95. PMID: 22024310.
      View in: PubMed
    60. Walsh M, Thomas SG, Howard JC, Evans E, Guyer K, Medvecz A, Swearingen A, Navari RM, Ploplis V, Castellino FJ. Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography. J Extra Corpor Technol. 2011 Sep; 43(3):162-7. PMID: 22164456.
      View in: PubMed
    61. Castellino FJ, Donahue DL, Navari RM, Ploplis VA, Walsh M. An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood. 2011 Jan 06; 117(1):283-9. PMID: 20858853.
      View in: PubMed
    62. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010 Jul; 6(7):1073-84. PMID: 20624119.
      View in: PubMed
    63. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. Cancer Manag Res. 2009 Dec 10; 1:167-76. PMID: 21188135.
      View in: PubMed
    64. Navari RM. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86. PMID: 19929251.
      View in: PubMed
    65. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010 Aug; 18(8):951-6. PMID: 19756773.
      View in: PubMed
    66. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009 Mar; 10(4):629-44. PMID: 19284365.
      View in: PubMed
    67. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009; 69(5):515-33. PMID: 19368415.
      View in: PubMed
    68. Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1733-42. PMID: 18983233.
      View in: PubMed
    69. Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008 Jul; 9(7):774-85. PMID: 18600583.
      View in: PubMed
    70. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate. J Clin Oncol. 2008 May 20; 26(15_suppl):9576. PMID: 27950226.
      View in: PubMed
    71. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008 Nov; 112(1):197-201. PMID: 18064563.
      View in: PubMed
    72. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007 Dec; 16(12):1977-85. PMID: 18042005.
      View in: PubMed
    73. Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007 Nov; 15(11):1285. PMID: 17375339.
      View in: PubMed
    74. Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007 Jan; 5(1):51-9. PMID: 17239326.
      View in: PubMed
    75. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006 Oct; 2(5):591-602. PMID: 17026451.
      View in: PubMed
    76. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct; 12(5):341-7. PMID: 17034670.
      View in: PubMed
    77. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar; 11(1):137-51. PMID: 16503832.
      View in: PubMed
    78. Navari RM. Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 2006 Feb; 32(1):50-4. PMID: 16427741.
      View in: PubMed
    79. Busquets L, Guillen H, DeFord ME, Suckow MA, Navari RM, Castellino FJ, Prorok M. Cathepsin E is a specific marker of dysplasia in APC mouse intestine. Tumour Biol. 2006; 27(1):36-42. PMID: 16340248.
      View in: PubMed
    80. Reinbolt RE, Shenk AM, White PH, Navari RM. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2005 Aug; 30(2):175-82. PMID: 16125033.
      View in: PubMed
    81. Navari RM, Reinbolt RE, Shenk AM, White PH. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Clin Oncol. 2005 Jun; 23(16_suppl):8069. PMID: 27946487.
      View in: PubMed
    82. Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005 Jul; 13(7):529-34. PMID: 15700131.
      View in: PubMed
    83. Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2004 Oct; 4(5):715-24. PMID: 15485308.
      View in: PubMed
    84. Price N, Reddy GK, Jain VK, Navari R. Highlights from: The 40th Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA. Support Cancer Ther. 2004 Jul 01; 1(4):201-6. PMID: 18628142.
      View in: PubMed
    85. Suckow MA, Gutierrez LS, Risatti CA, Wolter WR, Taylor RE, Pollard M, Navari RM, Castellino FJ, Paoni NF. The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. Cancer Lett. 2004 Jun 25; 209(2):165-9. PMID: 15159018.
      View in: PubMed
    86. Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest. 2004; 22(4):569-76. PMID: 15565815.
      View in: PubMed
    87. Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL, Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8. PMID: 15493359.
      View in: PubMed
    88. Navari RM. Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists. Support Cancer Ther. 2004 Jan 01; 1(2):89-96. PMID: 18628185.
      View in: PubMed
    89. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep; 37(9):1276-86. PMID: 12921512.
      View in: PubMed
    90. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. J Support Oncol. 2003 Jul-Aug; 1(2):89-103. PMID: 15352652.
      View in: PubMed
    91. White PH, Kuhlenschmidt HL, Vancura BG, Navari RM. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2003 May; 25(5):438-43. PMID: 12727041.
      View in: PubMed
    92. Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41. PMID: 12115394.
      View in: PubMed
    93. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 01; 94(1):25-36. PMID: 11815957.
      View in: PubMed
    94. Anderson AK, Nemecek JE, Navari RM. International study in premedical education. Acad Med. 2001 Nov; 76(11):1158. PMID: 11704521.
      View in: PubMed
    95. Navari RM, Stocking CB, Siegler M. Preferences of patients with advanced cancer for hospice care. JAMA. 2000 Nov 15; 284(19):2449. PMID: 11074772.
      View in: PubMed
    96. Navari R, Horner Catt J, Siegler M. A prisoner with chronic myeloid leukemia. Bone Marrow Transplant. 1999 Nov; 24(9):1037-9. PMID: 10556966.
      View in: PubMed
    97. Navari RM. Use of placebos in delayed-emesis studies. J Clin Oncol. 1999 May; 17(5):1648-50. PMID: 10334561.
      View in: PubMed
    98. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5. PMID: 9917226.
      View in: PubMed
    99. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73. PMID: 9552067.
      View in: PubMed
    100. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997 Aug; 15(8):2966-73. PMID: 9256141.
      View in: PubMed
    101. Kris MG, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V, Ferguson BB, Allman DS, Pizzo BA, Baker TW, Fernando IJ, Chernoff SB. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997 May; 15(5):2135-8. PMID: 9164228.
      View in: PubMed
    102. Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997 Feb; 8(2):181-5. PMID: 9093728.
      View in: PubMed
    103. Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH, Fitts D. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7. PMID: 9010987.
      View in: PubMed
    104. Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D, Wentz A. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest. 1997; 15(4):297-303. PMID: 9246149.
      View in: PubMed
    105. Miller AA, Lipton A, Henderson IC, Navari R, Mulagha MT, Cooper J. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer. 1996 Aug 15; 78(4):789-93. PMID: 8756373.
      View in: PubMed
    106. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9. PMID: 8708713.
      View in: PubMed
    107. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995 Sep; 13(9):2408-16. PMID: 7666101.
      View in: PubMed
    108. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8. PMID: 7738628.
      View in: PubMed
    109. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994 Oct; 12(10):2204-10. PMID: 7931490.
      View in: PubMed
    110. Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R, Navari R, Ahmann F, Zelenakas K, Heffernan M, Knight RD. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994 Sep 12; 154(17):1935-44. PMID: 8074597.
      View in: PubMed
    111. Navari RM, Province WS, Perrine GM, Kilgore JR. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer. 1993 Jul 15; 72(2):583-6. PMID: 8319191.
      View in: PubMed
    112. Richards EW, Long CL, Nelson KM, Tohver OK, Pinkston JA, Navari RM, Blakemore WS. Protein turnover in advanced lung cancer patients. Metabolism. 1993 Mar; 42(3):291-6. PMID: 8487646.
      View in: PubMed
    113. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75. PMID: 1453211.
      View in: PubMed
    114. Richards EW, Long CL, Nelson KM, Pinkston JA, Navari RM, Geiger JW, Gandy RE, Blakemore WS. Glucose metabolism in advanced lung cancer patients. Nutrition. 1992 Jul-Aug; 8(4):245-51. PMID: 1498456.
      View in: PubMed
    115. Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Garber JE, Henderson IC, Navari RM, et al. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab. 1991 Jul; 73(1):99-106. PMID: 1646219.
      View in: PubMed
    116. Navari RM. Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. J Clin Oncol. 1989 Jul; 7(7):943-6. PMID: 2544688.
      View in: PubMed
    117. Witherspoon RP, Navari R, Storb R, Sullivan KM, Doney K, Beatty P, Lum LG, Thomas ED. Treatment of marrow graft recipients with thymopentin. Bone Marrow Transplant. 1987 Apr; 1(4):365-71. PMID: 3332144.
      View in: PubMed
    118. Sheehy TW, Navari RM. Hypothermia. Ala J Med Sci. 1984 Oct; 21(4):374-81. PMID: 6507795.
      View in: PubMed
    119. Navari RM, Buckner CD, Clift RA, Storb R, Sanders JE, Stewart P, Sullivan KM, Williams B, Counts GW, Meyers JD, et al. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med. 1984 Apr; 76(4):564-72. PMID: 6424464.
      View in: PubMed
    120. Navari RM, Sullivan KM, Springmeyer SC, Siegel MS, Meyers JD, Buckner CD, Sanders JE, Stewart PS, Clift RA, Fefer A, et al. Mycobacterial infections in marrow transplant patients. Transplantation. 1983 Nov; 36(5):509-13. PMID: 6356515.
      View in: PubMed
    121. Navari RM, Sharma P, Deeg HJ, McDonald GB, Thomas ED. Pneumatosis cystoides intestinalis following allogeneic marrow transplantation. Transplant Proc. 1983 Jun; 15(2):1720-4. PMID: 6349056.
      View in: PubMed
    122. Navari RM, Sheehy TW, McLean BK, Sutton FD. The peripheral blood smear in heat stroke. An aid to diagnosis. Ala J Med Sci. 1983 Apr; 20(2):137-40. PMID: 6859439.
      View in: PubMed
    123. Navari RM, Carter J, Hillman RS. Bone marrow necrosis in acute leukemia. Acta Haematol. 1983; 69(3):158-63. PMID: 6404098.
      View in: PubMed
    124. Navari RM, Ploth DW, Tatum RK. Renal adenocarcinoma associated with multiple simple cysts. JAMA. 1981 Oct 16; 246(16):1808-9. PMID: 7277672.
      View in: PubMed
    125. Kontos HA, Wei EP, Dietrich WD, Navari RM, Povlishock JT, Ghatak NR, Ellis EF, Patterson JL. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol. 1981 Apr; 240(4):H511-27. PMID: 7223903.
      View in: PubMed
    126. Wei EP, Dietrich WD, Povlishock JT, Navari RM, Kontos HA. Functional, morphological, and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in cats. Circ Res. 1980 Jan; 46(1):37-47. PMID: 7349916.
      View in: PubMed
    127. Navari RM, Wei EP, Kontos HA, Patterson JL. Oxygen consumption of pial arteries. Am J Physiol. 1979 Jan; 236(1):H151-6. PMID: 434166.
      View in: PubMed
    128. Navari RM, Wei EP, Kontos HA, Patterson JL. Comparison of the open skull and cranial window preparations in the study of the cerebral microcirculation. Microvasc Res. 1978 Nov; 16(3):304-15. PMID: 34775.
      View in: PubMed
    129. Kontos HA, Wei EP, Raper AJ, Rosenblum WI, Navari RM, Patterson JL. Role of tissue hypoxia in local regulation of cerebral microcirculation. Am J Physiol. 1978 May; 234(5):H582-91. PMID: 645924.
      View in: PubMed
    130. Navari RM, Patterson JL. Inhibition of rat bronchiolar oxygen consumption by plasma proteins. J Appl Physiol Respir Environ Exerc Physiol. 1978 May; 44(5):659-65. PMID: 649466.
      View in: PubMed
    131. Kontos HA, Wei EP, Navari RM, Levasseur JE, Rosenblum WI, Patterson JL. Responses of cerebral arteries and arterioles to acute hypotension and hypertension. Am J Physiol. 1978 Apr; 234(4):H371-83. PMID: 645875.
      View in: PubMed
    132. Navari RM, Rosenblum WI, Kontos HA, Patterson JL. Mass transfer properties of gases in fluorocarbons. Res Exp Med (Berl). 1977 Jun 29; 170(2):169-80. PMID: 882714.
      View in: PubMed
    133. Rosenblum WI, Navari RM, Levasseur JE, Patterson JL. In vitro depression of tissue oxygen uptake by liquid fluorocarbon prepared as artificial blood. Proc Soc Exp Biol Med. 1977 Mar; 154(3):346-50. PMID: 846993.
      View in: PubMed
    134. Navari RM. Laboratory experiments using nicotine. J Chem Educ. 1974 Nov; 51(11):748-50. PMID: 4423654.
      View in: PubMed
    135. Bryant SC, Navari RM. Effect of plasma proteins on oxygen diffusion in the pulmonary capillaries. Microvasc Res. 1974 Jan; 7(1):120-30. PMID: 4132368.
      View in: PubMed
    136. Navari RM, Gainer JL, Hall KR. Transport in human plasma. Aerosp Med. 1971 Oct; 42(10):1123-4. PMID: 5095512.
      View in: PubMed
    137. Navari RM, Gainer JL. Prediction of the sigma effect in blood flow. Biorheology. 1968 Sep; 5(3):237-9. PMID: 5737957.
      View in: PubMed
    Navari's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (397) concept(s)
    _
    Co-Authors Expand Description
    See all (2) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Physical Neighbors Expand Description
    _